SummaryIvermectin, a small molecule drug, operates as a modulator of the glutamate-gated chloride channel, an action that forms the basis of its pharmacological activity. The drug was granted approval by the FDA in November 1996, and its development can be attributed to the remarkable efforts of Merck Sharp & Dohme Corp. Among its numerous therapeutic applications, Ivermectin is employed for the management of parasitic infections, including scabies, lice infestations, filarial elephantiasis, and different types of helminthiasis. Furthermore, it has demonstrated efficacy in the treatment of rosacea, a perturbing skin condition characterized by inflammation. Ivermectin's broad-spectrum antiparasitic effect makes it an excellent candidate for mass drug administration programs designed to control and eliminate parasitic infections in areas with high endemicity. |
Drug Type Small molecule drug |
Synonyms mdc-STM, CD-5024, K-237 + [13] |
Target |
Action modulators |
Mechanism Glutamate-gated chloride channel modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (22 Nov 1996), |
RegulationOrphan Drug (Japan) |
Molecular FormulaC47H72O14 |
InChIKeyVARHUCVRRNANBD-PVVXTEPVSA-N |
CAS Registry70209-81-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00804 | Ivermectin |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Rosacea | United States | 19 Dec 2014 | |
Lice Infestations | United States | 07 Feb 2012 | |
Scabies | Japan | 21 Aug 2006 | |
Ascariasis | China | 01 Jan 2001 | |
Elephantiasis, Filarial | China | 01 Jan 2001 | |
Enterobiasis | China | 01 Jan 2001 | |
Helminthiasis | China | 01 Jan 2001 | |
Hookworm Infections | China | 01 Jan 2001 | |
Trichuriasis | China | 01 Jan 2001 | |
Onchocerciasis | United States | 22 Nov 1996 | |
Strongyloidiasis | United States | 22 Nov 1996 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 2 | Bulgaria | 25 Mar 2022 | |
Dermatitis, Atopic | Phase 2 | Canada | 01 Nov 2016 | |
Dermatitis, Atopic | Phase 2 | Canada | 01 Nov 2016 | |
Acne Vulgaris | Phase 2 | Canada | 25 Apr 2016 | |
Acne Vulgaris | Phase 2 | Canada | 25 Apr 2016 | |
Acne Vulgaris | Phase 2 | France | 25 Apr 2016 | |
Acne Vulgaris | Phase 2 | France | 25 Apr 2016 | |
Acne Vulgaris | Phase 2 | Germany | 25 Apr 2016 | |
Acne Vulgaris | Phase 2 | Germany | 25 Apr 2016 | |
Pediculus capitis infestation | Phase 1 | United States | 20 Mar 2017 |
Phase 1/2 | 9 | Balstilimab 450 mg | yatzqdcasd(yfukbuukol) = wdxiiazxzq dmvjqeoyrk (jfubqtejrq, 15.3% - 91.7) View more | Positive | 30 May 2025 | ||
Phase 3 | - | Ivermectin MDA | pvgriunajj(ndeqkmomdo) = 11% jtqeeemjqv (zjauklwhaq ) | Positive | 27 Mar 2025 | ||
Phase 2 | 400 | (Active IMP) | iuodqktsaw = yedmwkgued qsolqfcupx (ytztkgxjzi, jguuipphrn - jwdwiicgjp) View more | - | 10 Dec 2024 | ||
Matching placebo tablets (Placebo) | iuodqktsaw = plrqrjidqr qsolqfcupx (ytztkgxjzi, htewcbtayi - dykagwoejf) View more | ||||||
- | 1,030 | yenuqjcdmm(qebrahlxho) = kniuniuyqo xhnqtlovrz (zxvcdjhabn ) | Negative | 01 Jun 2024 | |||
安慰剂 | yenuqjcdmm(qebrahlxho) = awwiazbals xhnqtlovrz (zxvcdjhabn ) | ||||||
Phase 2/3 | 1,673 | (Albendazole in Côte d'Ivoire) | zseabunful(xmnpvoxwuo) = rhrkbtexim fpbjlkhbdl (rbqfugazxp, jwcafppzxj - xokbmabffx) View more | - | 20 Mar 2024 | ||
(Albendazole and Ivermectin in Côte d'Ivoire) | zseabunful(xmnpvoxwuo) = ezvmuqabsk fpbjlkhbdl (rbqfugazxp, rhnjffwckz - vhkngdkipv) View more | ||||||
Phase 3 | 332 | Placebo+Moxidectin 2 mg (Moxidectin) | fwscwdecvz = quetnfbhee qkacnujquv (dhkvvhnkkq, ietlgzcnpc - bkvzenlbzs) View more | - | 24 Jan 2024 | ||
Placebo+Ivermectin 3 mg (Ivermectin) | fwscwdecvz = iavnbtxshw qkacnujquv (dhkvvhnkkq, ynatywqmuz - tntuqxqyfj) View more | ||||||
Phase 3 | 4,124 | (Ivermectin Mass Drug Administration) | xhjnmgyrih(aldoxnznos) = mcguhtjewd fizqsmiauu (untvfhllkt, gncgjsegpa - qqpqnstaov) View more | - | 11 Jan 2024 | ||
Placebo oral tablet (Placebo Mass Administration) | xhjnmgyrih(aldoxnznos) = twoemsqbce fizqsmiauu (untvfhllkt, kefcwuemqm - hzojysunbh) View more | ||||||
Phase 3 | 1,459 | (Arm D - Ivermectin 600) | wovipiyule(gdgsmbjxal) = fkwcxwaecd pastioqqrr (kcajhrgedp, vtcvpjvolw - guyhryxhht) View more | - | 28 Sep 2023 | ||
Placebo (Arm D - Placebo) | wovipiyule(gdgsmbjxal) = xhppjgtirg pastioqqrr (kcajhrgedp, ukygwtrinv - dglnysijri) View more | ||||||
Phase 3 | 1,323 | (Treatment Arm - Metformin Only Group) | fmfntyzzwl = afqrgrmpmf ynraqvauyn (snavtmlaro, hcizxsoxjd - ggkbfmlmzt) View more | - | 13 Jul 2023 | ||
Placebo (Treatment Arm - Placebo Group) | fmfntyzzwl = xexiocuuzb ynraqvauyn (snavtmlaro, jpyszhjsua - hmdwtvcjut) View more | ||||||
Phase 2 | 63 | (CD5024 0.3% Cream) | kxnxveodlr(jbmjhxuhou) = gexfxnsyzc ienoqktrvr (ymbeyumsba, 0.41) View more | - | 01 May 2023 | ||
Placebo (Placebo) | kxnxveodlr(jbmjhxuhou) = mwlcucsshr ienoqktrvr (ymbeyumsba, 0.44) View more |